All In Biotech

NDA 022122 · Haleon US Holdings

Voltaren Arthritis Pain

Diclofenac Sodium · Topical

Last checked: Nov 20, 2026Latest source record: Aug 7, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Oct 17, 2007

Approved uses

2

Original approval plus efficacy supplements

Registered trials

492

123 Phase 3, 29 recruiting

FAERS reports

101,833

50,966 serious, 9,959 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 11, 2025.

Uses • for the temporary relief of arthritis pain ONLY in the following areas: o hand, wrist, elbow (upper body areas) o foot, ankle, knee (lower body areas) • this product may take up to 7 days to work for arthritis pain; it is not for immediate relief. If no pain relief in 7 days, stop use.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VOLTAREN ARTHRITIS PAIN · DICLOFENAC SODIUM 1% · GEL, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Diclofenac" as an intervention, any sponsor and status, largest first.

All 492 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective23,949
  • product use in unapproved indication11,995
  • off label use10,311
  • pain10,013
  • fatigue9,014
  • product use issue8,022
  • rash7,842
  • rheumatoid arthritis7,286
  • product administered at inappropriate site7,061
  • abdominal discomfort6,878
  • arthralgia6,813
  • drug effective for unapproved indication6,788

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,074
20051,133
20061,113
20071,326
20081,507
20091,550
20101,878
20112,386
20122,241
20131,114
20141,643
20153,496
20164,866
20173,849
20184,046
20193,933
202010,738
202115,424
20228,874
20239,932
20249,046
20256,972
20263,685

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,435 on PubMed

Sponsor: Haleon US Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.